ACXP
Acurx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$1.06
-0.02 (-2.30%)
Current Price
| Previous Close | $1.08 |
| Open | $1.08 |
| Day High | $1.10 |
| Day Low | $1.05 |
| Volume | 56,157 |
Stock Information
| Shares Outstanding | 5.47M |
| Cash Equivalents | $10.66M |
| Net Income | $-7.51M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.80M |
| EPS (TTM) | $-2.67 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-5.07M |
| Income | $-7.51M |
| Book/sh | $1.74 |
| Cash/sh | $1.95 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 3.80 |
| Current Ratio | 3.88 |
Returns & Margins
| ROA | -55.92% |
| ROE | -128.11% |
Ownership
| Insider Ownership | 2.31% |
| Institutional Ownership | 3.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.61 |
| P/B | 0.61 |
Analyst Data
| Recommendation | none |
| Target Price | $17.00 |
Technical Indicators
| SMA20 | $1.20 |
| SMA50 | $1.32 |
| SMA200 | $2.00 |
| RSI | 22.73 |
| ATR | 0.0590 |
| Shares Float | 5.14M |
| Short Float | 2.06% |
| Short Ratio | 1.21 |
| Volatility | -2.05 |
| Rel Volume | 0.80 |
Performance History
| Week | -7.02% |
| Month | -20.90% |
| Quarter | -23.74% |
| 6 Months | -48.54% |
| YTD | -61.59% |
| Year | -83.72% |
| 3 Years | -98.98% |
| 5 Years | -98.90% |
| 10 Years | -99.33% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.06 | 58,300 |
| 2026-10-26 | $1.09 | 64,000 |
| 2026-10-23 | $1.13 | 22,200 |
| 2026-10-22 | $1.14 | 26,500 |
| 2026-10-21 | $1.15 | 21,000 |
| 2026-10-20 | $1.14 | 67,300 |
| 2026-10-19 | $1.14 | 51,100 |
| 2026-10-16 | $1.10 | 164,700 |
| 2026-10-15 | $1.17 | 98,300 |
| 2026-10-14 | $1.15 | 80,800 |
| 2026-10-13 | $1.20 | 97,600 |
| 2026-10-12 | $1.28 | 80,800 |
| 2026-10-09 | $1.27 | 40,200 |
| 2026-10-08 | $1.25 | 74,300 |
| 2026-10-07 | $1.30 | 78,000 |
| 2026-10-06 | $1.31 | 41,300 |
| 2026-10-05 | $1.31 | 109,700 |
| 2026-10-02 | $1.27 | 79,400 |
| 2026-10-01 | $1.26 | 64,600 |
| 2026-09-30 | $1.26 | 130,500 |
| 2026-09-29 | $1.30 | 161,600 |
| 2026-09-28 | $1.34 | 52,800 |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on ACXP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,091,983 | $14,123,227 | $14,577,768 | $12,092,776 |
| Net Non Operating Interest Income Expense | $125,445 | $20,124 | - | - |
| Operating Expense | $8,091,983 | $14,123,227 | $14,577,768 | $12,092,776 |
| General And Administrative Expense | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Interest Income | $125,445 | $20,124 | - | - |
| Interest Income | $125,445 | $20,124 | - | - |
| Normalized Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income From Continuing And Discontinued Operation | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Common Stockholders | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Including Noncontrolling Interests | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Net Income Continuous Operations | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Pretax Income | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Interest Income Non Operating | $125,445 | $20,124 | - | - |
| Operating Income | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-5.32 | $-17.45 | $-23.00 | $-22.40 |
| Basic EPS | $-5.32 | $-17.45 | $-23.00 | $-22.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| EBITDA (Bullshit earnings) | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| EBIT | $-8,091,983 | $-14,123,227 | $-14,577,768 | $-12,092,776 |
| Diluted Average Shares | $1,498,793 | $808,168 | $633,578 | $540,820 |
| Basic Average Shares | $1,498,793 | $808,168 | $633,578 | $540,820 |
| Diluted NI Availto Com Stockholders | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Research And Development | $1,834,506 | $5,403,836 | $6,043,597 | $4,754,271 |
| Selling General And Administration | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Other Gand A | $6,257,477 | $8,719,391 | $8,534,171 | $7,338,505 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-10-07
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Assets | $7,689,535 | $3,857,963 | $7,709,123 | $9,376,706 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $7,689,535 | $3,857,963 | $7,709,123 | $9,376,706 |
| Prepaid Assets | $85,018 | $100,123 | $105,776 | $264,955 |
| Receivables | $48,417 | $51,127 | $129,159 | $0 |
| Other Receivables | $48,417 | $51,127 | $129,159 | - |
| Cash Cash Equivalents And Short Term Investments | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Cash And Cash Equivalents | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Cash Financial | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,420,943 | $3,242,842 | $3,042,438 | $2,061,685 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $2,420,943 | $3,242,842 | $3,042,438 | $2,061,685 |
| Payables And Accrued Expenses | $2,381,932 | $2,705,212 | $2,326,131 | $1,518,790 |
| Payables | $6,802 | $4,787 | $3,809 | $29,539 |
| Other Payable | $6,802 | $4,787 | $3,809 | $29,539 |
| Equity | ||||
| Common Stock Equity | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Equity Gross Minority Interest | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Stockholders Equity | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Retained Earnings | $-75,288,494 | $-67,321,956 | $-53,218,853 | $-38,641,085 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $-38,641,085 |
| Other Equity Adjustments | - | - | - | $-38,641,085 |
| Other | ||||
| Ordinary Shares Number | $2,348,113 | $851,534 | $723,411 | $581,380 |
| Share Issued | $2,348,113 | $851,534 | $723,411 | $581,380 |
| Tangible Book Value | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Invested Capital | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Working Capital | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Total Capitalization | $5,268,592 | $615,121 | $4,666,685 | $7,315,021 |
| Additional Paid In Capital | $80,554,738 | $67,936,225 | $57,871,070 | $45,944,478 |
| Capital Stock | $2,348 | $852 | $14,468 | $11,628 |
| Common Stock | $2,348 | $852 | $14,468 | $11,628 |
| Pensionand Other Post Retirement Benefit Plans Current | $39,011 | $537,630 | $716,307 | $542,895 |
| Current Accrued Expenses | $2,375,130 | $2,700,425 | $2,322,322 | $1,489,251 |
| Treasury Shares Number | - | - | $0 | - |
| Total Partnership Capital | - | - | $-53,218,853 | $-38,641,085 |
Fetched: 2026-10-07
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Cash Flow From Continuing Operating Activities | $-6,787,782 | $-10,383,431 | $-9,800,885 | $-7,542,290 |
| Operating Gains Losses | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,040 | $0 | - | - |
| Issuance Of Capital Stock | $6,797,112 | $6,405,757 | $5,944,250 | $3,695,182 |
| Financing Cash Flow | $10,637,169 | $6,615,956 | $8,163,322 | $3,695,195 |
| Cash Flow From Continuing Financing Activities | $10,637,169 | $6,615,956 | $8,163,322 | $3,695,195 |
| Net Common Stock Issuance | $6,796,072 | $6,405,757 | $5,944,250 | $3,695,182 |
| Common Stock Issuance | $6,797,112 | $6,405,757 | $5,944,250 | $3,695,182 |
| Other | ||||
| End Cash Position | $7,556,100 | $3,706,713 | $7,474,188 | $9,111,751 |
| Beginning Cash Position | $3,706,713 | $7,474,188 | $9,111,751 | $12,958,846 |
| Changes In Cash | $3,849,387 | $-3,767,475 | $-1,637,563 | $-3,847,095 |
| Proceeds From Stock Option Exercised | $3,841,097 | $210,199 | $2,219,072 | $13 |
| Common Stock Payments | $-1,040 | $0 | - | - |
| Change In Working Capital | $-390,964 | $284,089 | $1,010,773 | $1,248,125 |
| Change In Payables And Accrued Expense | $-408,779 | $200,404 | $980,753 | $1,217,776 |
| Change In Prepaid Assets | $15,105 | $5,653 | $159,179 | $30,349 |
| Change In Receivables | $2,710 | $78,032 | $-129,159 | $0 |
| Stock Based Compensation | $1,569,720 | $3,435,583 | $3,766,110 | $3,302,361 |
| Net Income From Continuing Operations | $-7,966,538 | $-14,103,103 | $-14,577,768 | $-12,092,776 |
| Other Non Cash Items | - | - | $559,583 | $430,680 |
| Pension And Employee Benefit Expense | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-10-07